{
  "docId": "019dd923-5ca1-7489-b636-bc879d1b6d64",
  "docSlug": "17680cec2cbd3510",
  "documentTitle": "Accelerated Access Review UK Mapping",
  "authorId": "Deloitte",
  "authorName": "Deloitte",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.333,
  "pageNumber": 11,
  "pageCount": 109,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "initiative_list",
  "function": "prioritize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": [
    "headline_text",
    "numbered_list"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b636-bc879d1b6d64/11",
  "deckHref": "/decks/019dd923-5ca1-7489-b636-bc879d1b6d64",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b636-bc879d1b6d64.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b636-bc879d1b6d64#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.9,
        "x": 0.04,
        "y": 0.2
      },
      "kind": "list",
      "text": "1. Further review of pharma pathway opportunities and future proof for agile pathways\n2. Further review of medtech pathway to standardise and improve parity with pharma\n3. Future proof for precision medicine pathway\n4. Lightly regulate and develop systems to support adoption of digital health technologies\n5. Review organisational mandates and alignment to support adoption\n6. Funding of innovation, system incentives and contracting mechanisms in the NHS\n7. Role of data to support the end-to-end pathway and adoption of innovation\n8. Assess cultural barriers to collaborative working, e.g. facilitate earlier dialogue\n9. Clinical development environment and incentives for NHS involvement\n10. Reimbursement methodologies to incorporate early access and RWE\n11. Promote patient engagement throughout the end-to-end pathway\n12. Role of regional centres e.g. AHSNs as test beds and drivers of innovation",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "33980872-4f3f-4568-970c-2aab2f78b342",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.04,
        "y": 0.11
      },
      "kind": "paragraph",
      "text": "Based on our research, interviews and workshops, we recommend the following opportunities to take forward into Phase 2",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a57a25d-115a-41a1-a0ae-f45c71ee707c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.04,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Stakeholder interviews, workshops and Deloitte analysis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "27a019d8-ac28-464e-8664-a3915cbd4279",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.45,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Top areas for review in phase 2",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b04724f-a2e3-49ef-8016-97cb390b0fdc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 10,
      "beatId": "aacd1ccc-bd28-4624-b7f6-626b3a9a4a01",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The document highlights the consequences of not addressing these challenges, such as limited access to new treatments and technologies.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "216c31e8-2aee-4a6b-81ea-25d4d04ac422",
      "evidence": "The document highlights the consequences of not addressing the challenges, such as limited access to new treatments and technologies.",
      "position": 0,
      "objective": "What are the consequences of not improving access to medical innovations?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}